• Ascendis Pharma EPS for the quarter ending March 31, 2025 was $-1.67, a 33.32% decline year-over-year.
• Ascendis Pharma 2024 annual EPS was $-7.07, a 23.64% decline from 2023.
• Ascendis Pharma 2023 annual EPS was $-9.25, a 15.54% decline from 2022.
• Ascendis Pharma 2022 annual EPS was $-10.96, a 32.3% increase from 2021.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.